Validation and Comparison of the Therapeutic Efficacy of Boron Neutron Capture Therapy Mediated By Boron-Rich Liposomes in Multiple Murine Tumor Models

Abstract
Boron neutron capture therapy (BNCT) was performed at the University of Missouri Research Reactor in mice bearing CT26 colon carcinoma flank tumors and the results were compared with previously performed studies with mice bearing EMT6 breast cancer flank tumors. Mice were implanted with CT26 tumors subcutaneously in the caudal flank and were given two separate tail vein injections of unilamellar liposomes composed of cholesterol, 1,2-distearoyl-sn-glycer-3-phosphocholine, and K[nido-7-CH3(CH2)15–7,8-C2B9H11] in the lipid bilayer and encapsulated Na3[1-(2'-B10H9)-2-NH3B10H8] within the liposomal core. Mice were irradiated 30 hours after the second injection in a thermal neutron beam for various lengths of time. The tumor size was monitored daily for 72 days. Despite relatively lower tumor boron concentrations, as compared to EMT6 tumors, a 45 minute neutron irradiation BNCT resulted in complete resolution of the tumors in 50% of treated mice, 50% of which never recurred. Median time to tumor volume tripling was 38 days in BNCT treated mice, 17 days in neutron-irradiated mice given no boron compounds, and 4 days in untreated controls. Tumor response in mice with CT26 colon carcinoma was markedly more pronounced than in previous reports of mice with EMT6 tumors, a difference which increased with dose. The slope of the dose response curve of CT26 colon carcinoma tumors is 1.05 times tumor growth delay per Gy compared to 0.09 times tumor growth delay per Gy for EMT6 tumors, indicating that inherent radiosensitivity of tumors plays a role in boron neutron capture therapy and should be considered in the development of clinical applications of BNCT in animals and man.

Introduction
Boron neutron capture therapy (BNCT) is a binary form of radiation therapy that involves the selective delivery of boron to target tissues, followed by irradiation with thermal neutrons. When irradiated with low-energy neutrons (<0.4 eV), 10B, a naturally occurring isotope of boron, captures a neutron and undergoes a nuclear reaction that results in the release of an alpha particle and a lithium nucleus [1–3]. These particles have a high Linear Energy Transfer (LET) and short track lengths (5–9 μm), resulting in significant radiation killing effect in an area roughly equivalent to one cell diameter [4,5]. In general, it is intended that the boron delivery agents, as well as the low energy neutron beam, have very little biologic effect by themselves [6]. In this respect, cell killing selectivity is maximized in those tissues with high concentrations of 10B which are irradiated [7].

*University of Missouri, Department of Veterinary Medicine and Surgery, 900 East Campus Dr., Columbia, MO 65211, United States; †University of Missouri, International Institute of Nano & Molecular Medicine, 1514 Research Park Dr., Columbia, MO 65211, United States; ‡University of Missouri Research Reactor, 1513 Research Park Dr., Columbia, MO 65211, United States; §Idaho National Laboratory, 2525 Fremont Ave, Idaho Falls, ID 83402, United States

© 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1936-5233/17
http://dx.doi.org/10.1016/j.tranon.2017.05.003
Similar to other forms of high LET radiation therapy, the radiobiology of BNCT is complex [8,9]. While the maximum therapeutic effect of BNCT is realized from the boron neutron capture reaction products, there are several other dose sources which contribute to the total dose delivered during BNCT [10,11]. Gamma rays are produced during the BNCT reaction and hydrogen neutron capture [12]. The thermal neutron beam at the MURR contains acceptable levels of fast neutrons and gamma rays remaining after the neutron filters [13]. Fast neutrons produce interact with hydrogen and produce high LET recoil protons through elastic scatter. High LET protons are also produced when $^{14}$N captures a thermal neutron. The total physical dose delivered in a BNCT treatment is the sum of all of the physical dose components [10]. Based on the beam characteristics as shown in Table 1, there are two variables that determine total dose delivered to a tissue: the tissue boron concentration and the time length of irradiation [14]. The total biologic effective dose is much more complex, and must be determined experimentally with very specific endpoints [15].

BNCT research has been ongoing for over 50 years, including several direct clinical investigations in human patients with cancer [11,16–26]. While some efficacy has been shown in the human treatment of glioblastoma, head and neck cancer, and melanoma, the main shortcomings of BNCT have been in terms of neutron delivery, boron delivery, and prudent use of animal models of human disease [21,24,26–28]. While most BNCT facilities still use a nuclear reactor as a neutron source, filtering methods have improved since the initial investigations into this therapy. These advances have resulted in improved neutron spectra, allowing reduced gamma and fast neutron dose components, as well as the use of epithermal neutrons to allow for deeper penetration into tissues and skin sparing [14,29–31]. Currently, there remains a need for new boron-delivery compounds and a critical assessment of clinical uses. Ideally, these new boron compounds should be non-toxic, bear a high boron payload, and feature selective delivery to malignant tissues [2,32,33].

The need for appropriate selection of tumor models for BNCT has been demonstrated by the limited success of early trials to treat glioblastoma multiforme [1,16,18,19]. These results are not surprising, given the difficulty associated with treating this aggressive brain malignancy [34]. BNCT has already met with a measure of success when applied to different clinical scenarios including treatment of melanoma and recurrent tumors of the head and neck [21,26,28,35–37]. In an effort to develop new, more cancer-specific boron delivery compounds and direct them to alternative tumor models, Kueffer et al. demonstrated BNCT in mice bearing EMT6 mammary tumors using boron-rich liposomes as a delivery system [38]. These liposomal nanoparticles deliver two boron clusters compounds, $\text{K}(\text{nido-7-CH}_3(\text{CH}_2)_{15}-7,8-\text{C}_2\text{B}_9\text{H}_{11})$ (MAC) and $\text{Na}_3[1(2'-\text{B}_3\text{H}_9)2-\text{NH}_2\text{B}_10\text{H}_{13}]$ (TAC), which carry a high boron payload [24,25]. These compounds are incorporated into liposomes, with MAC in the lipid bilayer membrane, and TAC in the hydrophilic liposome core. Liposomes containing both MAC and TAC are then administered intravenously and, by means of the enhanced permeability and retention (EPR) effect of neoplastic vasculature, accumulate preferentially in the tumor [39–41]. In mice with allograft EMT6 mammary carcinoma tumors, delivery of these compounds via a double-injection protocol resulted in tumor boron concentrations as high as 67.8 μg B per gram of tumor tissue, and a 30 minute irradiation nearly doubled the time required for EMT6 tumors to reach 500 mm$^3$ [38]. This study seeks to further validate these compounds in a second murine tumor model, namely CT26 colon carcinoma, and to compare BNCT efficacy with results from the previous EMT6 experiments.

### Results

#### Biodistribution Studies

Studies were carried out to evaluate the boron concentrations in blood, tumor and normal organs in mice bearing CT26 tumors. These experiments were designed to mirror the studies done involving mice with EMT6 tumors [38]. Once tumors were approximately 100–150 mm$^3$, mice were administered two separate MAC/TAC liposome injections of 200 μL via the lateral tail vein delivered 24 h apart, resulting in a total boron dose of 360–371 μg B per injection. Blood, liver, spleen, kidney, tumor, skin, and tail were collected at necropsy at multiple time points and were subsequently analyzed for their boron content using inductively coupled plasma atomic emission spectroscopy (ICP-OES). The biodistribution results are presented in Figure 1. An average peak tumor boron concentration of 36 ppm was observed 18 hours after the second injection (n = 9), though boron levels in the tumor remained relatively consistent from 18 to 72 hours. The maximum tumor to blood boron ratio of 3.1:1 occurred 72 hours after the second injection, at which time the average tumor boron concentration was 28 ppm (n = 6) (Supporting information Table 1).

#### Irradiation Studies

After biodistribution studies were completed, a series of neutron irradiation studies were performed to evaluate the therapeutic response of CT26 tumors to BNCT using these liposomes. The mice were irradiated for 30, 45, 60, or 90 minutes. The irradiation started 30 hours after the second boron injection. Figure 2 illustrates the tumor growth delay after a 45 minute irradiation, comparing untreated controls (n = 29), mice receiving only a 45 minute neutron irradiation (n = 8), and mice receiving a 45 minute irradiation 30 hours after the boron injection protocol (n = 8). The 45 minute neutron irradiation resulted in a delivered dose of 8.3 Gy to the BNCT-treated mice and 2.7 Gy to the neutron-only mice. The tumors of control mice reached 500 mm$^3$ in 7 days, the tumors of neutron-only mice reached 500 mm$^3$ in 21 days, and those of BNCT-treated mice required 41 days to reach the same volume. These values were all statistically different from one another (P = .00985). Additionally, 4 of the 8 mice in the BNCT-treated group experienced an at least temporary complete tumor regression, 2 of which remained in remission until the end of the study period (73 days after irradiation). No mice in the neutron-only group had resolution of their tumors after a 45 minute irradiation. A Kaplan–Meier curve demonstrating the time for tumors to triple in size is presented for different irradiation groups in Figure 3.

#### Dose–Response Comparison

As already discussed, the total physical dose delivered in BNCT is the sum of each of the dose components. Since the constituent dose

| Dose Component       | Physical Dose Rate |
|----------------------|--------------------|
| Gamma dose from beam | 3.4 cGy/min        |
| $^1$H capture photons| 1.4 cGy/min        |
| $^{14}$N capture protons | 1.1 cGy/min     |
| BNCT reaction (Li and He) | 0.43 cGy/min/ppm $^{10}$B |
contributions are directly influenced by filtration and neutron profiles, the derivation of dose components is specific for a given neutron beam. A dose–response comparison was made without distinguishing these two variables and is presented as Figure 4. For EMT6 tumors, a delivered dose of ~8.30 Gy (30 min irradiation) results in a relative tumor growth delay of 1.8 (18 days vs. 10 days). This response increases in a near-linear fashion to 2.4 (24 days vs. 10 days) after a delivered dose of ~16.60 Gy (60 min irradiation), resulting in a slope of \( m = 0.09 \) times delayed tumor growth per Gy delivered \( (R^2=0.9353) \). This effect is more pronounced in mice bearing CT26 tumors, where similar doses result in delays of 9.25 (37 days vs. 4 days) and 18.75 (75 days vs. 4 days), respectively, and an overall slope of \( m = 1.05 \) times delayed tumor growth per Gy \( (R^2=0.9889) \).

Figure 1. Mean boron concentration in tissue after a double injection of MAC/TAC liposomes in mice with CT26 tumors. Error bars indicate the standard deviation of the measurements.

Figure 2. Tumor growth delay after irradiation of multiple tumor models. This figure presents the mean tumor volume normalized to the tumor volume of that population at day 0. All non-control mice were irradiated for 45 minutes.
Boron Compounds

All animals in these studies received two separate injections of non-permeable liposome constructs containing MAC in the lipid bilayer, and TAC in the aqueous core. Liposome infusion was initially fractionated due to limitations on the injectable volume in mice, and the 24 hour time point was chosen based on pharmacokinetic properties. These compounds are not evaluable non-invasively as studied, though our laboratory is actively developing similar agents that function as CT or MRI contrast agents, which would allow for evaluation of boron content without need for a biopsy [42–44]. The compounds studied here are also only passively targeted to the tumor via the EPR effect. While we have seen improved tumor targeting using functionalized nanoparticles over non-functionalized nanoparticles, we have not actively targeted our liposome platform (unpublished data).

Biodistribution Studies

The peak tumor boron concentration of 36 ppm observed in CT26 mice is markedly less than the 68 ppm in EMT6 tumors as reported by Kueffer et al. [38] There were several notable differences in the development of the tumors identified during this study. The growth rate of CT26 tumors is markedly different from that of EMT6 tumors. While tumors would generally take longer to reach a 100 mm³ volume in the mouse flanks (14 days vs. 7 days for EMT6 tumors), once measureable, the tumors grew at a much more rapid rate, resulting in the inclusion of several larger tumors in the biodistribution analysis. As reported earlier, we also noted that tumor size is inversely proportional to tumor boron concentration (Supporting Materials). [38] The wider range of tumor sizes in the CT26 mice would allow the inclusion of mice with larger tumors in the data, resulting in an overall decrease in the average tumor boron content for these mice. Also noteworthy is that, as tumor grows larger, the EMT6 tumors tend to develop a necrotic central region, whereas the CT26 tumors do not. Other factors which may have altered boron delivery to tumors include variability in tumor necrosis, vasculogenesis and permeability [40].

Irradiation Studies

Even though the tumor to blood boron ratio was poor at the 30 hour time point, we carried out the irradiation experiment to directly compare results of this study with the previous EMT6 experiment. Despite lower tumor boron concentrations in CT26 tumors, we observed a very robust response to BNCT. Indeed, 50% of the tumors treated with 8.3 Gy completely resolved, and half of these tumors did not recur for the life of the mouse. While Heber et al. recently published data demonstrating the complete resolution of
some tumors using these same liposome compounds for BNCT of squamous cell carcinoma of the hamster check pouch, complete resolution in mice receiving a single BNCT session had not been seen by our group until the current studies [45]. There are at least two contributing factors to the noted response, both relating to the differences in the biology of these tumors. The first factor is a difference in the inherent radiosensitivity of the two tumor types. A marked antitumor response was noted in the mice with CT26 tumors that received only neutron irradiation, whereas a much less robust response was noted in the neutron-only mice in the EMT6 studies. In fact, in the initial studies using CT26 tumors, mice received a 90 minute irradiation resulting in complete resolution of the tumors in all mice (both BNCT (16.6 Gy) and neutron only controls (5.3 Gy)). The observed difference in biologic response with no change in the physical delivery of the radiation suggests an inherent biologic difference in the sensitivity of these tumors to radiation.

The other factor likely contributing to this difference is a result of the different growth patterns of CT26 tumors compared to EMT6 tumors. As noted above, CT26 tumors develop more slowly, but, once measureable, grow more quickly than EMT6 tumors. This observation suggests that the fraction number of cells which are actively dividing (growth fraction) in CT26 tumors is larger than in EMT6 tumors. Additionally, even as CT26 tumors reach sizes up to 2 cm in diameter, they retain an ellipsoid to spherical shape, whereas EMT6 tumors become flattened and scabbed. These observations correlate with early data indicating a large central area of focal necrosis in EMT6 tumors. A large area of necrosis is likely to inhibit the uptake of boron compounds due to inadequate blood supply. As a result, the boron distribution in these EMT6 tumors is likely more heterogeneous than in CT26 tumors of equal size. This heterogeneity would prevent the sterilization of tumor cells, evidenced by the regrowth of all EMT6 tumors, whereas complete local control for more than 90 days was seen in 25% of the mice with CT26 tumors. The presence of necrotic regions, and likely hypoxic regions, could also directly contribute to differences in radiosensitivity of the two tumor lines.

**Dose–Response Comparison**

Only total dose was considered in the dose–response comparison, without regards specifically to the presence of boron. Consequently, the doses reported are in terms of physical dose, rather than biologic dose, which was not possible to determine due to the absence of an observable endpoint. Thus, while the particles of the BNCT reaction have a higher linear energy transfer than the other components of the beam, they were weighted the same as the doses delivered to the neutron-only mice. It is worth noting that no dramatic change of slope was noted in the dose response curves, which would have potentially indicated an increased biologic effect at the higher doses, which included dose from the BNCT reaction. It is also worth noting that this study was performed in in vivo models treated with BNCT, which is in contrast to the majority of the studies comparing different cell lines to treatment with high LET radiation.

At all doses, the radiation delivered included both high LET radiation (BNCT components, recoil and capture protons, etc.) and low LET radiation (gamma rays), though only the mice that were irradiated after having been given boron compounds had alpha particle and lithium nucleus high LET components. Response to radiation therapy was measured by means of tumor growth delay, which incorporates all forms of cell loss, including necrotic, apoptotic and mitotic cell death. The increased biologic effect from high LET radiation is usually attributed to increased complexity of DNA damage in the form of double strand breaks and local multiply damaged sites resulting from a denser ionization pattern [46,47]. This model of biologic effectiveness is supported by the relative indifference of high LET radiation to hypoxia, phase in the cell cycle and fractionation, as DNA repair is minimal when complex DNA damage occurs [15]. This model, however, does not account for the differences seen between cell lines in the current study. While cell kinetics and level of hypoxia could vary between the two cell lines, the current understanding of high LET killing from the BNCT reaction suggests that cell kill should be similar. The difference is most likely due to a difference in inherent radiosensitivity [48]. One component of inherent radiosensitivity is radiation-induced apoptosis, which has been shown to be non-p53-mediated in high LET radiation, which is in contrast to the p53-dependent apoptosis associated with low LET radiation [49–51]. However, in this study, apoptosis is likely not the only component, as the minimum tumor size is achieved 15 days after treatment in mice with CT26 tumors treated with BNCT, and apoptosis is expected to be seen within 72 hours of irradiation.

Ideally, multiple tumor lines should be evaluated in an attempt to systematically identify potential targets for BNCT. The logistical limitations of the current study required transport of mice to the MU Research Reactor where neutron irradiation was conducted and back to a separate mouse facility for monitoring. Transport of mice in this manner is not feasible using immune-compromised mice, and thus we were limited to tumor cell lines syngenic to the mice used in the experiments. Nevertheless, this data demonstrates that inherent radiosensitivity of the target plays a role in the outcome of boron neutron capture therapy, and suggests that appropriate selection of tumor systems for the application of BNCT is imperative. This data also reinforces the concept that relative biologic effectiveness (RBE) is dependent on multiple factors, including endpoint and tumor model.

**Materials and Methods**

**Compounds**

Boron compounds were prepared using previously published methods and subsequently formulated into liposomal suspensions [38,52–54]. The \( m \), diameter (mean diameter of the volume distribution, representing the center of gravity of the distribution) of formulated liposomes ranged from 89.1 nm to 109.2 nm as determined by dynamic light scattering. The boron concentrations of the liposome formulations were 1800–1853 ppm for the irradiation studies, and 2384 ppm for the biodistribution studies.

**Cell Culture and Tumor Induction**

CT26.CL25 cells were purchased from American Type Culture Collection and cultured in Dulbecco’s Modified Eagle Media supplemented with 10% FBS as recommended by American Type Culture Collection. Cells in log phase were dissociated by incubation with TrypLE buffer (Life Technologies) for 10 min, followed by addition of FBS-containing medium to terminate TrypLE digestion. Cells were then centrifuged at 323×g for 8 min at room temperature using Fisher Scientific Accuspin 3R centrifuge, and cell pellets were resuspended in PBS solution. Cells were counted using a Countess Automatic Cell Counter (Life Technologies). For tumor induction, CT26 cells (1×10⁶ cells/mouse) were inoculated into the right flank of female BALB/c mice having an average body weight of 20 ± 2 g.
following standard protocols [55]. Animals were purchased in groups of 12 mice (Harlan Laboratories) for tumor induction, and were assigned to either biodistribution or irradiation studies at induction.

**Biodistribution Studies**

CT26 tumors were developed in the right flank of mice as described above. After the tumors reached a reliably measurable size (approximately 75 mm³), mice were administered two separate injections of 200 µL of the MAC/TAC liposome compound into the lateral tail vein, 24 hours apart. Mice were euthanized 18, 24, 30, 48, and 72 hours after the second liposome injection. Multiple tissues, including blood, liver, spleen, kidney, skin, tumor and tail were collected at the time of necropsy. Average tumor mass at the time of necropsy was 294.8 mg (range 84–634.7). Samples were digested and analyzed using ICP-OES as described previously by Kueffer et al. [38].

**Therapeutic Effect Studies**

CT26 tumors were developed in either the left or right flank of mice as described above. Once tumors reached a reliably measurable size (approximately 75 mm³), mice were administered two separate injections of 200 µL of the MAC/TAC liposome compound into the lateral tail vein, 24 hours apart. Average tumor size at the time of irradiation was 122.6 mg (range 57.8–216.1) for CT26, and 60.1 mg (range 21.6–103.9) for EMT6. Mice were transported to the University of Missouri Research Reactor 30 hours after the second injection, where they were anesthetized and placed in the thermal neutron beam for 30, 45, 60, or 90 minutes. Prior to irradiation, mice were anesthetized with a combination of 10 mg/kg xylazine and 80 mg/kg ketamine administered i.p. Cu/Au flux wires were affixed to the right or left flank (over the tumor) using tape before it was placed in a positioning gantry as described previously by Kueffer et al. [38] The average neutron flux was previously determined to be 8.8 x 10⁸ neutrons/cm² s (±7%) integrated over the (thermal) energy range of 0.0 to 0.414 eV. The neutron spectrum validation has previously been described by Brockman et al. [14] Irradiation times varied from 30 to 90 minutes, and doses were determined using the sum of dose components from Table 1. After the irradiation procedure, mice were monitored with daily tumor measurements until humane endpoints were met. All procedures involving live animals were done in accordance with the Institutional Animal Care and Use Committee at the University of Missouri.

**Data Analysis**

Tumor volumes in mm³ were calculated using the equation $V = \frac{4}{3} \pi w^2 d$, where $l$ is the length (greatest diameter), $w$ is the width (perpendicular to greatest diameter) and $d$ is the depth of the tumor, all in mm. Biodistribution plots and tumor growth curves were constructed using Microsoft Excel 2013. In the dose–response comparison, the unit Growth Delay Effect, which was the quotient of the time to 350 mm³ of the treatment group divided by the time 350 mm³ of the control group, was used to account for the difference in growth rates between CT26 and EMT6 tumors. Time-to-event analysis was performed using the Kaplan–Meier method, and outcomes among groups were compared using the log-rank test. Survival analysis was performed using SigmaPlot 12.0. Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.tranon.2017.05.003.

**References**

[1] Sweet W (1997). Early history of development of boron neutron capture therapy of tumors. J Neurooncol 33, 19–26.
[2] Hawthorne MF (1993). Role of Chemistry in the Development of Boron Neutron Capture Therapy of Cancer. Angew Chem Int Ed Engl 32, 950–984. http://dx.doi.org/10.1002/anie.199309501.
[3] Baum EM, Ernesti MC, Knox HD, Miller TR, and Watson AM (2009). Nuclides and Isotopes Chart of the Nuclides. 17th Edition.
[4] Claesson K (2011). Radiobiological effects of alpha-particles from Astatine-211: From DNA damage to cell death.
[5] Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Cogodini JM, and Wilson JG (1998). The Chemistry of Neutron Capture Therapy. (Chem. Rev. 1998, 98, 1515. Published on the Web May 20, 1998). Chem Rev 98, 2389–2390.
[6] Barth RF (2003). A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 62. http://dx.doi.org/10.1016/b02699929.
[7] Dorn III RV (1994). Boron neutron capture therapy (BNCT): a radiation oncology perspective. Int J Radiat Oncol Biol Phys 28, 1189–1201.
[8] González S and Santa Cruz G (2012). The photon-isoeffect dose in boron neutron capture therapy. Radiat Res 178, 609–621. http://dx.doi.org/10.1667/rst12944.1.
[9] Codere JA, Turtocce JC, Riley KJ, Birns PJ, Harling OK, and Kiger WS (2003). Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat 2, 355–375.
[10] Codere J and Morris G (1999). The radiation biology of boron neutron capture therapy. Radiat Res 151, 1–18. http://dx.doi.org/10.1667/rr2944.1.
[11] Hopewell J, Morris G, Schwint A, and Codere J (2011). The radiobiological principles of boron neutron capture therapy: a critical review. Appl Radiat Isot 69, 1756–1759. http://dx.doi.org/10.1016/j.apradiso.2011.04.019.
[12] Mughabghab S, Divadenam M, and NE, H. (1981). Neutron Resonance Data. Jnt. J. Mod. Phys. B 5, 1515. Published on the Web May 20, 1998).
[13] Kankaanranta L, Seppala T, Koivunoro H, Valimaki P, et al (2012). Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer. J Neurooncol 109, 238–240.
[14] Kankaanranta L, Seppala T, Koivunoro H, Saarialho K, et al (2007). Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys 69, 475–482. http://dx.doi.org/10.1016/j.ijrobp.2007.03.039.
[15] Kankaanranta L, Seppala T, Koivunoro H, Saarialho K, et al (2012). Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys 82, 75. http://dx.doi.org/10.1016/j.ijrobp.2010.09.057.
[16] Kankaanranta L, Seppala T, Koivunoro H, Valimaki P, et al (2011). Boron neutron capture therapy in the treatment of brain tumors: clinical trials at the finnish facility using boronophenylalanine. J Neurooncol 101, 134–139.
[17] Kankaanranta L, Seppala T, Koivunoro H, Saarialho K, et al (2007). Boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. J Radiat Oncol Biol Phys 80, 369–376. http://dx.doi.org/10.1016/j.ijrobp.2011.02.031.
[18] Kankaanranta L, Seppala T, Koivunoro H, Saarialho K, et al (2007). Boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. J Radiat Oncol Biol Phys 80, 369–376. http://dx.doi.org/10.1016/j.ijrobp.2011.02.031.
glioblastoma multiforme: clinical studies in Sweden. *J Neurooncol* **62**, 135–144. http://dx.doi.org/10.1007/s11095-015-1718-y.

[24] Henriksson R, Capala J, Michanek A, Lindahl SA, Salfod LG, Franzén L, Blomquist E, Westlin JE, and Bergenheim AT (2008). Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). *Radiat. Oncol.* **88**, http://dx.doi.org/10.1016/j.radonc.2006.04.015.

[25] Yamamoto T, Masumura A, Nakai K, Shibata Y, Endo K, Sakurai F, Kishi T, Kumada H, Yamamoto K, and Tori Y (2004). Current clinical results of the Tsukuba BNCT trial. *Appl Radiat Isot* **61**, 1089–1093. http://dx.doi.org/10.1016/j.apradiso.2004.05.010.

[26] Menéndez PR, Roeh BMC, Pereira MD, Casal MR, Gonzalez SJ, Feld DB, Santa Cruz GA, Kessler J, Longhino J, Blaumann H, et al (2009). BNCT for skin melanoma in extremes: Updated Argentine clinical results. *Appl Radiat Isot* **67**, 550–553. http://dx.doi.org/10.1016/j.apradiso.2009.03.020.

[27] Gavin PP, Leathers CC, DeHaan CC, and Bauer WW (1994). Biodistribution of boron in dogs with spontaneous intracranial tumors following borocaptate sodium administration. *Cancer Res* **54**(5), 1259–1263.

[28] Mishima YY, Ichihashi MM, Honda CC, and Shiono MM (1992). Advances in the control of human cutaneous primary and metastatic melanoma by thermal neutron capture therapy. Neutron Capture, 1992.

[29] Rogus RD, Harling OK, and Yanch JC (1994). Mixed field dosimetry of epithermal neutron beams for boron neutron capture therapy at the MITR-II research reactor. *Med Phys*.

[30] POzzi EC, Thorp S, Brockman J, Miller M, Nigg D, and Hawthorne M (2011).

[31] Minoru S, Ituro K, Teruhito A, Junichi H, Kenichi Y, Miyuki N, Yoshihiro K, Lacroix M, Abi-Said D, Fourney D, Gokaslan Z, Shi W, DeMonte F, Lang F, Hawthorne M and Lee M (2003). A critical assessment of boron target neutron sources for BNCT small-animal research. *Intercalibration of physical neutron dosimetry for the RA-3 and MURR thermal research reactor.*

[32] Henriksson R, Capala J, Michanek A, Lindahl SA, Salfod LG, Franzen L, Kamada K, Yamamoto K, and Torii Y (2004). Current clinical results of the Tsukuba BNCT trial. *Int J Radiat Biol* **79**, 611–621.

[33] Mori E, Takahashi A, Yamakawa N, Kirita T, and Ohnishi T (2009). High LET radiation: A Comparative Study. *Radiol.* **219**(2), 394–404.

[34] Hawthorne M and Lee M (2003). A critical assessment of boron target compounds for boron neutron capture therapy. *J Neurooncol* **62**, 33–45.

[35] Feakes D, Shelly K, and Hawthorne M (1994). Na3[B20H17NH3]: Synthesis of Amine Derivatives of the Polyhedral Borane Anion [B(20)H(18)](4^-) and liposomal delivery to murine tumors. *J Radiat Res (Tokyo).* http://dx.doi.org/10.1093/jrr/109.9.

[36] Kueffer PJ, Maitz CA, Khan AA, Schuster SA, Shlyakhtina NI, Jalisatgi SS, Brockman JD, Nigg DW, and Hawthorne MF (2013). Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes. *Proc Natl Acad Sci USA.* http://dx.doi.org/10.1073/pnas.1303437110.

[37] Matsumura Y and Maeda H (1986). A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. *Cancer Res* **46**, 6387–6392.

[38] Fang J, Nakamura H, and Maeda H (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Adv Drug Deliv Rev* **63**, 136–151. http://dx.doi.org/10.1016/j.addr.2010.04.009.

[39] Hawthorne M and Shelly K (1997). Liposomes as drug delivery vehicles for boron agents. *J Neurooncol* **33**, 53–58.

[40] Goswami LN, Ma L, Chakravarty S, Cai Q, Jalisatgi SS, and Hawthorne MF (2013). Discrete Nanomolecular Polyhedral Borane Scaffold Supporting Multiple Gadolinium(III) Complexes as a High Performance MRI Contrast Agent. *Inorg Chem* **52**, 1694–1700. http://dx.doi.org/10.1021/ic3017613.

[41] Heber EM, Hawthorne MF, Kueffer PJ, Garabalino MA, Thorp SI, Pozzi EC, Monti Hughes A, Maia CT, Jalisatgi SS, and Hawthorne MF (2013). cRGD Peptide-Conjugated Icosahedral closo-B122 Core Carrying Multiple Ga3+–DOTA Chelates for oxβ3 Integrin-Targeted Tumor Imaging (MRI). *Inorg Chem* **52**, 1701–1709. http://dx.doi.org/10.1021/ic303254k.

[42] Arumugam T, Menahem E, Sivasankaran R, Pande VP, and Aunsworth AS (2000). Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model. *Proc Natl Acad Sci U S A* **107**, 16077–16081. http://dx.doi.org/10.1073/pnas.1001073107.

[43] Tannock I, Britton R, Hill R, and Harrington L (2013). Basic Science of Oncology. Fifth Edition. McGraw-hill Education.

[44] Durante M (2014). New challenges in high-energy particle radiobiology. *Br J Radiol.* http://dx.doi.org/10.1259/bjr.20130626.

[45] Harrington K, Jankowska P, and Hingorani M (2007). Molecular biology for the radiation oncologist: the 5R’s of radiobiology meet the hallmarks of cancer. *Clin Oncol (R Coll Radiol)* **19**, 561–571. http://dx.doi.org/10.1016/j.cto.2007.04.009.

[46] Heber EM, Hawthorne MF, Kueffer PJ, Garabalino MA, Thorp SI, Pozzi EC, Monti Hughes A, Maia CT, Jalisatgi SS, and Hawthorne MF (2013). A Trimodal Closomer Drug-Delivery System Tailored with Tracing and Targeting Capabilities. *Chem A Eur J* **19**, 12757–12772. http://dx.doi.org/10.1002/chem.201302413.